Subcutaneously CM310/Placebo in Patients With Moderate-to-Severe Atopic Dermatitis (AD)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
This is a multi-center, randomized, double blind, placebo-controlled phase IIb study to evaluate the efficacy, safety, PK, PD and immunogenicity of CM310 in moderate-severe AD subjects. The study consists of 3 periods, a up-to-4-week Screening Period, a 16-week randomized Treatment Period and a 8-week Safety Follow-up Period.
Epistemonikos ID: dc35fd02cd8956f5426ab81d395e18365357708d
First added on: May 08, 2024